Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Fitterfly is a health technology enterprise focused on metabolic wellness, utilizing innovative, customized technology and scientific principles to assist individuals in managing conditions like diabetes, obesity, heart disease, and other metabolic issues. Their offerings, including Fitterfly Diabetes Prime and Fitterfly Weight Loss, present thorough and tailored strategies that feature real-time blood glucose monitoring through a non-invasive Continuous Glucose Monitoring (CGM) device, as well as personalized plans for diet, exercise, stress management, and sleep, all complemented by dedicated health coaches. These initiatives aim to empower individuals to reach significant health milestones with results that genuinely impact their lives. Fitterfly’s methodology is anchored in rigorous behavioral therapy, emphasizing the cultivation of healthy habits through a focus on nutrition, physical activity, stress reduction, and sleep hygiene. Their digital therapeutic solutions are clinically validated, demonstrating successful outcomes such as an average decrease of 1.96 points in HbA1c levels within three months, alongside an average weight reduction of 5 kg, showcasing the effectiveness of their programs in promoting overall health. Ultimately, Fitterfly strives to transform the way people approach their metabolic health through a blend of technology and personalized care.
Description
Introducing a versatile API designed to seamlessly integrate with your diabetes management system, offering tailored therapeutic education and enhanced insights into blood glucose level fluctuations. This solution enables real-time risk predictions, fostering greater personalization and improved system regulation, while adeptly managing complex living scenarios characterized by rapid glucose variations. With advancements in telemedicine and retrospective analysis, patients receive robust decision-support tools. Currently, Hillo is developing the next iterations of its AI technology, which includes a therapeutic recommendation system aimed at preventing hypoglycemia and hyperglycemia, anticipated to achieve CE mark class IIB by 2020. Additionally, a new generation of the artificial pancreas is projected for release in 2021, addressing key limitations of existing systems through ultra-personalization driven by machine learning. This innovative approach marks the introduction of the first self-learning artificial intelligence capable of predicting blood glucose levels, aiming to secure a CE mark as a medical device, thereby transforming diabetes management for users. In essence, Hillo's advancements could significantly enhance the quality of life for individuals managing diabetes.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
Free
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Fitterfly
Founded
2016
Country
India
Website
www.fitterfly.com
Vendor Details
Company Name
Hillo
Country
France
Website
www.hillo.ai/